GlaxoSmithKline plc (GSK) Q3 2011 Earnings Call October 26, 2011 8:30 am ET Executives Andrew Witty - Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee Simon Dingemans - Chief Financial Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee Analysts Steve Scala - Cowen and Company, LLC, Research Division Mark Beards - Goldman Sachs Group Inc., Research Division Brian Bourdot - Barclays Capital, Research Division Gbola Amusa - UBS Investment Bank, Research Division Seamus Fernandez - Leerink Swann LLC, Research Division Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division Kerry Holford - Crédit Suisse AG, Research Division Graham Parry - BofA Merrill Lynch, Research Division Alexandra Hauber - JP Morgan Chase & Co, Research Division Florent Cespedes - Exane BNP Paribas, Research Division Presentation Andrew Witty Thank you very much, and thank you all for joining the call. I'm actually in Tokyo, and Simon Dingemans is in London. So we're relying on the technology, and if there is a time lag between the Q&A and my answers, trust me, it's not because we've moved Brentford to the other side of the world. I think it's particularly apt that I'm hosting today's call from Japan, given that our Japanese business has significantly contributed to this quarter's growth. Notably through the great uptake of Cervarix as part of the national HPV vaccination program, which started here earlier this year. Cervarix is 1 of more than 60 new products indication that GSK has launched in Japan since 2000, and we have the potential for up to a further 40 such launches over the next 5 years.
